公开(公告)号：WO2018022494A1

公开(公告)日：2018-02-01

申请号：PCT/US2017/043481

申请日：2017-07-24

Applicant: STC.UNM

Inventor： TIMMINS, Graham ,  LIU, Ke Jian Jim ,  ZHOU, Xixi

IPC: A61K31/395 ,  A61K45/06 ,  A61P31/06

Abstract: The present invention is directed to the discovery that pyrazinamide, a potent anti-tuberculosis agent acts through an entirely unexpected mechanism- through inhibition of the host enzyme poly ADP ribose polymerase ("PARP"). Thus, the present invention is directed to methods of treating: mycobacterial infections ( Mycobacterium ), especially M. tuberculosis using a PARP inhibitor, optionally in combination with at least one additional agent useful in the treatment of a mycobacterial infection, especially tuberculosis. Pharmaceutical compositions, especially including a pharmaceutical composition in oral or inhalation dosage form, comprising a PARP inhibitor, optionally in combination with an additional anti-mycobacterial agent, especially an additional anti-tuberculosis agent represent additional embodiments of the present invention.

Abstract translation: 本发明涉及通过抑制宿主酶多聚ADP核糖聚合酶（“PARP”）而发现吡嗪酰胺（一种有效的抗结核剂）通过完全意想不到的机制起作用。 因此，本发明涉及治疗：分枝杆菌感染（分枝杆菌），特别是M的方法。 任选地与至少一种可用于治疗分枝杆菌感染，特别是结核病的其他药剂组合使用。 包含PARP抑制剂的药物组合物，特别是包含口服或吸入剂型的药物组合物，任选地与另外的抗分枝杆菌剂，特别是另外的抗结核剂组合，代表本发明的另外的实施方案。